



Title	Economic Assessment of Mitral Valve Insufficiency Treatment
Agency	AETSA, Andalusian Agency for Health Technology Assessment Av. Innovación s/n. Edificio Renta Sevilla, 2ª planta, 41020 Seville, Spain; Tel: +34 955 407 233, Fax: +34 955 407 238; leda.ojeda.ext@juntadeandalucia.es, www.juntadeandalucia.es/salud/aetsa
Reference	ISBN 978-84-96990-24-1. www.juntadeandalucia.es/salud/servicios/contenidos/aetsa/pdf/AETSA_2006-3I_Insuf_valv_mitral.pdf

Aim

To compare the cost-effectiveness ratios of surgical strategies for mitral valve insufficiency from the health system perspective.

Conclusions and results

The chargeable costs for surgeries were 27 020 and 34 297 euros (EUR) for repair and replacement, respectively. Life expectancy was 14.486 years for repair and 11.766 years for replacement. The cost-effectiveness analysis of surgeries used to treat mitral valve insufficiency showed that the dominant alternative was intervention through repair, since it costs less and is more effective than replacement.

Methods

A Markov model was used to analyze cost-effectiveness. The health conditions considered were life and death, and life expectancy was used as the effectiveness measure in the cost-effectiveness analysis. The costs associated with surgeries and effectiveness were extracted from the literature.